- A U.S. court of appeals has affirmed a district court's ruling that Hanmi has not infringed AstraZeneca's (AZN) '504 patent.
- The court determined that "the written description limits 'alkaline salt' in the '504 patent to certain specifically named salts."
- Ultimately, this means the district court's ruling of noninfringement is upheld.
- AZN "respectfully disagrees" and will consider a "further appeal," Reuters notes.
- Full decision
at Zacks.com (Tue, 6:26PM)